Personalized Nanomedicines for Leukemia Patients

Project Information

PNANOMED

Grant agreement ID: 638035

DOI 10.3030/638035

Project closed

EC signature date 15 June 2015

Start date 1 July 2015

End date 30 June 2020

Funded under

• EXCELLENT SCIENCE - European Research Council (ERC)

Total cost € 1 499 750,00

EU contribution € 1 499 750,00

Coordinated by

MEDIZINISCHE HOCHSCHULE HANNOVER
Germany

Publications

Peer reviewed articles (18)

Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML

Author(s): Felicitas Thol, Razif Gabdoulline, Alessandro Liebich, Piroska Klement, Johannes Schiller, Christian Kandziora, Lothar Hambach, Michael Stadler, Christian Koenecke, Madita Flintrop, Mira Pankratz, Martin Wichmann, Blerina Neziri, Konstantin Büttner, Bennet Heida, Sabrina Klesse, Anuhar Chaturvedi, Arnold Kloos, Gudrun Göhring, Brigitte Schlegelberger, Verena I. Gaidzik, Lars Bullinger, Walter Fi
Published in: Blood, Issue 132/16, 2018, Page(s) 1703-1713, ISSN 0006-4971
Publisher: American Society of Hematology
DOI: 10.1182/blood-2018-02-829911

Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia

Author(s): Arnold Kloos, Konstantinos Mintzas, Lina Winckler, Razif Gabdoulline, Yasmine Alwie, Nidhi Jyotsana, Nadine Kattre, Renate Schottmann, Michaela Scherr, Charu Gupta, Felix F. Adams, Adrian Schwarzer, Dirk Heckl, Axel Schambach, Suzan Imren, R. Keith Humphries, Arnold Ganser, Felicitas Thol, Michael Heuser
Published in: Leukemia, 2020, ISSN 0887-6924
Publisher: Nature Publishing Group
DOI: 10.1038/s41375-020-0929-3

Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo

Author(s): Nidhi Jyotsana, Amit Sharma, Anuhar Chaturvedi, Ramachandramouli Budida, Michaela Scherr, Florian Kuchenbauer, Robert Lindner, Fatih Noyan, Kurt-Wolfram Sühs, Martin Stangel, Denis Grote-Koska, Korbinian Brand, Hans-Peter Vornlocher, Matthias Eder, Felicitas Thol, Arnold Ganser, R. Keith Humphries, Euan Ramsay, Pieter Cullis, Michael Heuser
Published in: Annals of Hematology, Issue 98/8, 2019, Page(s) 1905-1918, ISSN 0939-5555
Publisher: Springer Verlag
DOI: 10.1007/s00277-019-03713-y

Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia

Author(s): Anuhar Chaturvedi, Charu Gupta, Razif Gabdoulline, Nora M. Borchert, Ramya Goparaju, Stefan Kaulfuss, Kerstin Görlich, Renate Schottmann, Basem Othman, Julia Welzenbach, Olaf Panknin, Markus Wagner, Robert Geffers, Arnold Ganser, Felicitas Thol, Michael Jeffers, Andrea Haegebarth, Michael Heuser
Published in: Haematologica, 2020, Page(s) haematol.2019.236992, ISSN 0390-6078
Publisher: Ferrata Storti Foundation
DOI: 10.3324/haematol.2019.236992

Targeted Inhibition of the NUP98-NSD1 Fusion Oncogene in Acute Myeloid Leukemia

Author(s): Sagarajit Mohanty, Nidhi Jyotsana, Amit Sharma, Arnold Kloos, Razif Gabdoulline, Basem Othman, Courteney K. Lai, Renate Schottmann, Madhvi Mandhania, Johannes Schmoellerl, Florian Grebien, Euan Ramsay, Anitha Thomas, Hans-Peter Vornlocher, Arnold Ganser, Felicitas Thol, Michael Heuser
Published in: Cancers, Issue 12/10, 2020, Page(s) 2766, ISSN 2072-6694
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/cancers12102766

Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia

Author(s): Charu Gupta, Stefan Kaulfuss, Kerstin Görlich, Basem Othman, Anuhar Chaturvedi, Michael Heuser
Published in: Annals of Hematology, Issue 99/6, 2020, Page(s) 1415-1417, ISSN 0939-5555
Publisher: Springer Verlag
DOI: 10.1007/s00277-020-04001-w

Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without dose ramp-up

Author(s): Rabia Shahswar, Gernot Beutel, Razif Gabdoulline, Christian Koenecke, Dominik Markel, Matthias Eder, Michael Stadler, Gudrun Gohring, Brigitte Schlegelberger, Arne Trummer, Juergen Krauter, Felicitas Thol, Michael Heuser
Published in: Annals of Hematology, 2020, ISSN 0939-5555
Publisher: Springer Verlag
DOI: 10.1007/s00277-020-04181-5

Exploiting differential RNA splicing patterns: a potential new group of therapeutic targets in cancer

Author(s): Nidhi Jyotsana, Michael Heuser
Published in: Expert Opinion on Therapeutic Targets, Issue 22/2, 2017, Page(s) 107-121, ISSN 1472-8222
Publisher: Ashley Publications Ltd.
DOI: 10.1080/14728222.2018.1417390

Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation

Author(s): Michael Heuser, Razif Gabdoulline, Patrick Löffeld, Vera Dobbernack, Henriette Kreimeyer, Mira Pankratz, Madita Flintrop, Alessandro Liebich, Sabrina Klesse, Victoria Panagiota, Michael Stadler, Martin Wichmann, Rabia Shahswar, Uwe Platzbecker, Christian Thiede, Thomas Schroeder, Guido Kobbe, Robert Geffers, Brigitte Schlegelberger, Gudrun Göhring, Hans-Heinrich Kreipe, Ulrich Germing, Arnold Ga
Published in: Annals of Hematology, Issue 96/8, 2017, Page(s) 1361-1372, ISSN 0939-5555
Publisher: Springer Verlag
DOI: 10.1007/s00277-017-3027-5

Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?

Author(s): M. Heuser
Published in: Hematology, Issue 2016/1, 2016, Page(s) 24-32, ISSN 1520-4391
Publisher: American Society of Hematology
DOI: 10.1182/asheducation-2016.1.24

Epigenetics in myelodysplastic syndromes

Author(s): Michael Heuser, Haiyang Yun, Felicitas Thol
Published in: Seminars in Cancer Biology, 2017, ISSN 1044-579X
Publisher: Academic Press
DOI: 10.1016/j.semcancer.2017.07.009

Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate

Author(s): A Chaturvedi, M M Araujo Cruz, N Jyotsana, A Sharma, R Goparaju, A Schwarzer, K Görlich, R Schottmann, E A Struys, E E Jansen, C Rohde, C Müller-Tidow, R Geffers, G Göhring, A Ganser, F Thol, M Heuser
Published in: Leukemia, Issue 30/8, 2016, Page(s) 1708-1715, ISSN 0887-6924
Publisher: Nature Publishing Group
DOI: 10.1038/leu.2016.71

Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo

Author(s): A Chaturvedi, L Herbst, S Pusch, L Klett, R Goparaju, D Stichel, S Kaulfuss, O Panknin, K Zimmermann, L Toschi, R Neuhaus, A Haegebarth, H Rehwinkel, H Hess-Stumpp, M Bauser, T Bochtler, E A Struys, A Sharma, A Bakkali, R Geffers, M M Araujo-Cruz, F Thol, R Gabdoulline, A Ganser, A D Ho, A von Deimling, K Rippe, M Heuser, A Krämer
Published in: Leukemia, Issue 31/10, 2017, Page(s) 2020-2028, ISSN 0887-6924
Publisher: Nature Publishing Group
DOI: 10.1038/leu.2017.46

Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis

Author(s): F Thol, S Klesse, L Köhler, R Gabdoulline, A Kloos, A Liebich, M Wichmann, A Chaturvedi, J Fabisch, V I Gaidzik, P Paschka, L Bullinger, G Bug, H Serve, G Göhring, B Schlegelberger, M Lübbert, H Kirchner, M Wattad, D Kraemer, B Hertenstein, G Heil, W Fiedler, J Krauter, R F Schlenk, K Döhner, H Döhner, A Ganser, M Heuser
Published in: Leukemia, Issue 31/6, 2017, Page(s) 1286-1295, ISSN 0887-6924
Publisher: Nature Publishing Group
DOI: 10.1038/leu.2016.345

RNA interference efficiently targets human leukemia driven by a fusion oncogene in vivo

Author(s): N Jyotsana, A Sharma, A Chaturvedi, M Scherr, F Kuchenbauer, L Sajti, A Barchanski, R Lindner, F Noyan, K-W Sühs, D Grote-Koska, K Brand, H-P Vornlocher, M Stanulla, B Bornhauser, J-P Bourquin, M Eder, F Thol, A Ganser, R K Humphries, E Ramsay, P Cullis, M Heuser
Published in: Leukemia, Issue 32/1, 2017, Page(s) 224-226, ISSN 0887-6924
Publisher: Nature Publishing Group
DOI: 10.1038/leu.2017.269

Meningioma 1 is indispensable for mixed lineage leukemia-rearranged acute myeloid leukemia

Author(s): Amit Sharma, Nidhi Jyotsana, Razif Gabdoulline, Dirk Heckl, Florian Kuchenbauer, Robert K. Slany, Arnold Ganser, Michael Heuser
Published in: Haematologica, Issue 105/5, 2020, Page(s) 1294-1305, ISSN 0390-6078
Publisher: Ferrata Storti Foundation
DOI: 10.3324/haematol.2018.211201

In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site

Author(s): Anuhar Chaturvedi, Ramya Goparaju, Charu Gupta, Julia Weder, Thomas Klünemann, Michelle Maria Araujo Cruz, Arnold Kloos, Kerstin Goerlich, Renate Schottmann, Basem Othman, Eduard A. Struys, Heike Bähre, Denis Grote-Koska, Korbinian Brand, Arnold Ganser, Matthias Preller, Michael Heuser
Published in: Leukemia, Issue 34/2, 2020, Page(s) 416-426, ISSN 0887-6924
Publisher: Nature Publishing Group
DOI: 10.1038/s41375-019-0582-x

FLA‐IDA salvage chemotherapy combined with a seven‐day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia

Author(s): Rabia Shahswar, Gernot Beutel, Piroska Klement, Alina Rehberg, Razif Gabdoulline, Christian Koenecke, Dominik Markel, Hendrik Eggers, Matthias Eder, Michael Stadler, Lothar Hambach, Steve Ehrlich, Gudrun Göhring, Brigitte Schlegelberger, Elke Dammann, Marlene Reuter, Martin Wichmann, Blerina Neziri, Arnold Ganser, Felicitas Thol, Michael Heuser
Published in: British Journal of Haematology, Issue 188/3, 2019, ISSN 0007-1048
Publisher: Blackwell Publishing Inc.
DOI: 10.1111/bjh.16268

Intellectual Property Rights

Patent (2)

COMBINATION OF MIDH1 INHIBITORS AND DNA HYPOMETHYLATING AGENTS (HMA)

Application/Publication number: 18 742521
Date: 2018-07-25

MEANS AND METHODS FOR TREATING CANCER

Application/Publication number: 14 724722
Date: 2014-05-14